AI
ByCan Edison Scientific and Population Health Partners’ AI Build the Next $10 Billion Biotech?
Key Highlights The Deal at a Glance Announced on June 29, 2026, the partnership pairs PHP’s proven track…
Can Sanofi SA’s New AI-Enabled Innovation Hub in China Accelerate Global Drug Development and Reshape Biopharma Operations Across Asia?
Key Highlights: AI-Integrated Innovation Hubs Redefine Global R&D ModelsSanofi SA’s launch of its innovation and operations centre in…
Can Novartis AG’s $3 Billion AI-Driven Oncology Bet Redefine Precision Breast Cancer Treatment and Accelerate Next-Gen Drug Discovery?
Key Highlights: AI-Led Drug Discovery Accelerates Target Identification and ValidationNovartis AG’s acquisition of SNV4818 from Synnovation Therapeutics, Inc.…
How Will Emerging Drug Pricing Policies Reshape the Global Biopharma Industry in the Near and Long Term?
The global biopharmaceutical industry is entering a new policy-driven era as governments intensify efforts to control drug costs,…
Can Attovia Therapeutics’ Nasdaq IPO Signal a Broader Biotech Funding Revival Backed by Goldman Sachs and Deep Track Capital?
Key Highlights A Landmark Filing Reflecting Renewed Confidence in Biopharma Innovation Attovia Therapeutics’ decision to file for a…
Can OpenLoop’s Acquisition of Hey Revia Redefine How AI Automates Telehealth Communication for Thousands of Providers?
Key Highlights A Landmark Acquisition Strengthening OpenLoop’s Virtual Care Ecosystem OpenLoop, the Iowa-based telehealth infrastructure company known for…
